Alkem Laboratories financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹3,740cr+10.9% on Q1 FY26
Net profit
₹521cr−22.0% on Q1 FY26
EBITDA margin
20.5%−1.4 pts on Q1 FY26
EPS
₹43.49−21.7% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue3,7403,371+10.9%
EBITDA766739+3.7%
EBITDA margin20.5%21.9%−1.4 pts
Profit before tax772771+0.1%
Net profit521668−22.0%
EPS₹43.49₹55.56−21.7%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹3,740 crNet profit₹521 crNet margin13.9%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
60,612————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
9859851,206604591
529529449402390
1,6241,6241,0631,2141,397
61,779————
15,08114,71212,96512,66811,599
—+13.5%+2.3%+9.2%—
3,0323,0052,5122,2451,609
20.1%20.4%19.4%17.7%13.9%
2,6382,6232,1551,9461,299
2,2042,3512,2151,8111,007
14.6%16.0%17.1%14.3%8.7%
₹180.47₹192.54₹181.14₹150.21₹82.32
—+6.3%+20.6%+82.5%—
—1,9631,9131,9481,683
—−617−676−259−233
1,3461,3461,2371,6891,450
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALKEM₹5,070.00

Alkem Laboratories Ltd.

· Pharma & Health
₹ CrorePeersMANKINDTORNTPHARMIPCALABLUPINFORTISAUROPHARMALAURUSLABSBIOCONMcap ₹60,612 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————60,611.9
- Cash, Equiv & ST Investments591.0604.11,206.4985.2985.2
+ Minority Interest389.7402.3448.8528.8528.8
+ Total Debt1,396.71,214.01,062.81,623.51,623.5
Enterprise Value————61,779.0
Revenue11,599.312,667.612,964.514,712.315,081.3
Growth %, YoY—+9.2+2.3+13.5—
EBITDA1,609.52,245.52,512.23,005.23,032.2
Margin %13.8817.7319.3820.4320.11
EBIT1,299.01,946.22,155.02,623.22,637.6
Net Income1,006.81,811.52,215.42,351.22,204.2
Margin %8.6814.3017.0915.9814.62
EPS, Adj (current shares)82.32150.21181.14192.54180.47
Growth %, YoY—+82.5+20.6+6.3—
Cash from Operations1,682.51,948.11,912.81,963.0—
Capital Expenditures-232.9-259.3-675.6-617.3—
Free Cash Flow1,449.61,688.81,237.21,345.81,345.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Alkem Laboratories financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Alkem Laboratories (NSE: ALKEM) had a market capitalisation of ₹60,719 crore at the 29 October 2026 close (₹5,079.00 a share), a PE ratio of 28.1 on the last four quarters' profit and a price-to-book ratio of 4.39. In FY26 its consolidated net profit attributable to shareholders was ₹2,302 crore on revenue of ₹14,712 crore; in Q1 FY27 (April–June 2026) it was ₹520 crore, down 21.7% year on year. Its debt-to-equity ratio was 0.11 on 31 March 2026. Promoters held 49.70% of the shares on 30 June 2026.

Share price used
₹5,079.00 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 June 2026

Alkem Laboratories at a glance · consolidated

Market cap
₹60,719 Crat ₹5,079.00 · 29 Oct close
PE ratio (last 4 quarters)
28.126.4 on FY26 profit
Price to book (PB)
4.39book value ₹1,156.01 a share
ROE (FY26)
17.8%−1.6 pts vs FY25ROCE 17.6%
Debt to equity
0.11net cash ₹847 Cr
Promoter holding
49.70%−1.5 pts vs 31 Mar 202630 June 2026
Dividend yield
1.04%₹53 a share in 12 months
Net worth
₹13,820 Cr+15.3% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹1,346 Cr+8.8% vs FY25

Questions

What is the Alkem Laboratories PE ratio today?

Alkem Laboratories' PE ratio is 28.1 at the 29 October 2026 close (₹5,079.00 a share): a market capitalisation of ₹60,719 crore divided by consolidated net profit attributable to shareholders of ₹2,158 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹2,302 crore) it is 26.4.

What is the Alkem Laboratories PB ratio (price to book value)?

Alkem Laboratories' price-to-book (PB) ratio is 4.39 at the 29 October 2026 close: a market capitalisation of ₹60,719 crore divided by shareholders' equity (book value) of ₹13,820 crore on 31 March 2026. That is a book value of ₹1,156.01 per share against a share price of ₹5,079.00.

What is the Alkem Laboratories ROE and ROCE?

In FY26, Alkem Laboratories' return on equity (ROE) was 17.8% and its return on capital employed (ROCE) was 17.6%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 19.4% and ROCE 17.0%.

What is the Alkem Laboratories market cap?

Alkem Laboratories' market capitalisation was ₹60,719 crore at the 29 October 2026 close: 11.96 crore shares at ₹5,079.00 each.

Is Alkem Laboratories debt free?

No. Alkem Laboratories had borrowings of ₹1,624 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.11. Its cash and current investments were ₹2,470 crore, so it held net cash of ₹847 crore.

What is the Alkem Laboratories EPS?

Alkem Laboratories' basic earnings per share (EPS) were ₹192.51 in FY26, against ₹181.11 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹180.44.

What is the Alkem Laboratories debt to equity ratio?

Alkem Laboratories' debt-to-equity ratio was 0.11 on 31 March 2026: borrowings of ₹1,624 crore against total equity of ₹14,349 crore. A year earlier, on 31 March 2025, it was 0.09.

What is the Alkem Laboratories dividend yield?

Alkem Laboratories' dividend yield is 1.04% at the 29 October 2026 close: dividends of ₹53 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹5,079.00. They were ₹10 on 7 August 2026 and ₹43 on 20 February 2026 (interim).

What is the Alkem Laboratories free cash flow?

In FY26, Alkem Laboratories generated ₹1,963 crore of cash from operations and spent ₹617 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹1,346 crore. In FY25 it was ₹1,237 crore.

What is the Alkem Laboratories net worth?

Alkem Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹13,820 crore on 31 March 2026, up 15.3% from ₹11,985 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹60,719 crore at the 29 October 2026 close.

What is the Alkem Laboratories book value per share?

Alkem Laboratories' book value per share was ₹1,156.01 on 31 March 2026: shareholders' equity of ₹13,820 crore divided by the 11.96 crore shares in issue, up 15.3% from ₹1,002.50 a year earlier. The share price at the 29 October 2026 close was ₹5,079.00.

What is the Alkem Laboratories promoter holding?

Promoters held 49.70% of Alkem Laboratories on 30 June 2026, down 1.50 percentage points from 51.20% the previous quarter and down 3.34 percentage points from 53.04% a year earlier, according to the shareholding pattern filed with NSE.

What is the Alkem Laboratories dividend in 2026 and its record date?

In 2026, Alkem Laboratories has declared two dividends totalling ₹53 a share: ₹43 (interim) with record date 20 February 2026 and ₹10 with record date 7 August 2026.

What are the Alkem Laboratories latest quarterly results?

Alkem Laboratories' latest results are for Q1 FY27 (April–June 2026): consolidated net profit attributable to shareholders ₹520 crore, down 21.7% from ₹664 crore in Q1 FY26; revenue from operations ₹3,740 crore, up 10.9% year on year.

When are the Alkem Laboratories next results?

Alkem Laboratories has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the Alkem Laboratories shareholding pattern?

On 30 June 2026, Alkem Laboratories' shares were held by promoters 49.70%, foreign portfolio investors (FII/FPI) 10.42%, domestic institutions (DII) 22.63% (including mutual funds at 16.71%) and retail and other non-institutional investors 17.25%. Over the year, FII holding was up 1.31 percentage points from 9.11% and DII holding was up 0.83 percentage points from 21.80%.

What is the Alkem Laboratories revenue and profit in FY26?

In FY26 (April 2025–March 2026), Alkem Laboratories' consolidated net profit attributable to shareholders was ₹2,302 crore, up 6.3% from ₹2,165 crore in FY25, on revenue from operations of ₹14,712 crore (up 13.5%). Over three years, from FY23, net profit was up 133.9%.

How does the Alkem Laboratories PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Alkem Laboratories' PE ratio is 26.4, the lowest of the four: Mankind Pharma 53.3, Torrent Pharma 80.5 and Ipca Laboratories 42.8, a peer average of 58.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Alkem Laboratories compare with its peers?

On FY26 consolidated figures, against Mankind Pharma, Torrent Pharma and Ipca Laboratories: Alkem Laboratories' operating margin of 17.8% is the third highest of the four (Mankind Pharma 19.1%, Torrent Pharma 24.6%, Ipca Laboratories 16.2%; peer average 20.0%); its return on equity of 17.8% is the second highest of the four (Mankind Pharma 12.5%, Torrent Pharma 27.1%, Ipca Laboratories 15.2%; peer average 18.3%); its revenue growth over three years of 8.3% a year is the lowest of the four (Mankind Pharma 17.7% a year, Torrent Pharma 13.3% a year, Ipca Laboratories 15.6% a year; peer average 15.5% a year).

Alkem Laboratories vs Mankind Pharma: how do they compare?

In FY26, Alkem Laboratories earned net profit attributable to shareholders of ₹2,302 crore on revenue of ₹14,712 crore, against ₹1,913 crore on ₹14,278 crore for Mankind Pharma. Alkem Laboratories' operating margin was 17.8% (Mankind Pharma 19.1%) and its return on equity 17.8% (Mankind Pharma 12.5%). At the 29 October 2026 close, Alkem Laboratories' market capitalisation was ₹60,719 crore against ₹1,01,982 crore for Mankind Pharma, and its PE ratio on FY26 profit 26.4 against 53.3.

Where do these Alkem Laboratories figures come from?

From Alkem Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.